What the FDA labels say about taking them together
Methotrexate and sofosbuvir/velpatasvir/voxilaprevir
Sofosbuvir/velpatasvir/voxilaprevir's FDA label of July 14, 2025 names methotrexate in its drug interactions section; the methotrexate labels PlainMeds reads (4) do not name sofosbuvir/velpatasvir/voxilaprevir. The sofosbuvir/velpatasvir/voxilaprevir label: “Coadministration of VOSEVI with BCRP substrates is not recommended.”
Check it at the source: the methotrexate FDA label on DailyMed (effective May 27, 2026, Accord Healthcare Inc.); the sofosbuvir/velpatasvir/voxilaprevir FDA label on DailyMed (effective July 14, 2025, Gilead Sciences, Inc.).
What does the methotrexate label say about sofosbuvir/velpatasvir/voxilaprevir?
Methotrexate's label (effective May 27, 2026) and its 3 other brand-application labels do not name sofosbuvir/velpatasvir/voxilaprevir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed
What does the sofosbuvir/velpatasvir/voxilaprevir label say about methotrexate?
Sofosbuvir/velpatasvir/voxilaprevir label, drug interactionsCoadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (Vosevi), Gilead Sciences, Inc., effective July 14, 2025 (SPL set 17ffc094-8ca7-45d2-80d8-fd043bc9a221), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Methotrexate | Sofosbuvir/velpatasvir/voxilaprevir | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Psoriasis, Leukemia, lymphoma and myeloma, Breast cancer | Hepatitis C |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.158 per tablet 2.5 mg tablet | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once